Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?

Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma

(2018) Erin E. Burke et al.   Expert Opinion on Drug Metabolism & Toxicology

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

(2018) Jason Chesney et al.   JOURNAL OF CLINICAL ONCOLOGY

Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity.

(2018) Alan Anthoney et al.   JOURNAL OF CLINICAL ONCOLOGY

Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).

(2018) Robert Hans Ingemar Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncolytic Virotherapy: A Contest between Apples and Oranges

(2017) Stephen J. Russell et al.   MOLECULAR THERAPY

Targeted agents and immunotherapies: optimizing outcomes in melanoma

(2017) Jason J. Luke et al.   Nature Reviews Clinical Oncology

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives

(2017) Zong Sheng Guo et al.   Frontiers in Immunology

Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials

(2017) Ibrahim Ragab Eissa et al.   Frontiers in Oncology

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

(2016) Robert H. I. Andtbacka et al.   ANNALS OF SURGICAL ONCOLOGY

Developments in Intralesional Therapy for Metastatic Melanoma

(2016) Sarah Sloot et al.   Cancer Control

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment

(2015) Robert HI Andtbacka et al.   Journal for ImmunoTherapy of Cancer

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

(2014) Howard L Kaufman et al.   Journal for ImmunoTherapy of Cancer

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

(2012) E. M. Karapanagiotou et al.   CLINICAL CANCER RESEARCH

Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress

(2012) Balveen Kaur et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma

(2012) Evanthia Galanis et al.   MOLECULAR THERAPY

A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma

(2011) Tae-Ho Hwang et al.   MOLECULAR THERAPY

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

(2010) Howard L Kaufman et al.   Future Oncology

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses

(2009) H. Kishimoto et al.   MOLECULAR CANCER THERAPEUTICS

A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors

(2009) John Nemunaitis et al.   MOLECULAR THERAPY

A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

(2008) L. Vidal et al.   CLINICAL CANCER RESEARCH